EMA’s CHMP Issues Negative Opinion of Neratinib as Added Therapy in Early Stage HER2-positive Breast Cancer
News
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion of neratinib as an extended adjuvant treatment of early stage, HER-2 positive breast cancer. ... Read more